Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $369.13M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.59M
Average 0.26M
Returns on capital
Puma Biotechnology, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
23.9%
avg 67.0%
ROIC
20.4%
avg -52.1%
ROA
14.4%
avg -41.9%
Analysis
ROE is currently the strongest return metric at 23.9% versus its period average of 67.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Alan H. Auerbach | Founder, Chairman, President, Chief Executive Officer & Secretary | USD 1.98M | 56 | 7.26M | 14.27% |
Maximo F. Nougues | Chief Financial Officer & Principal Accounting Officer | USD 904.49K | 57 | 230.64K | 0.45% |
Douglas Hunt FRAPS | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer | USD 797.76K | 61 | — | — |
Kenneth Wiehe | Senior Vice President of Supply Chain & Manufacturing | — | — | — | — |
Roger L. Storms | Senior Vice President of Sales | — | — | — | — |
Heather Blaber | Senior Vice President of Marketing | — | — | — | — |
Pamela Wilson | Senior Vice President of Clinical Operations | — | — | — | — |
Gordon G. Esplin | Chief Accounting Officer | — | 58 | — | — |
Petra Rietschel | Senior Vice President of Clinical Development | — | — | — | — |
Mariann Ohanesian | Senior Director of Investor Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
17
$2.14M
Net Transaction Value
−$2.14M
Net selling
Most Active
AUERBACH ALAN H
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 11, 26Nov 11, 2026 | MILLER MICHAEL PATRICK Direct | Sell | $121.5K$121,456.50 |
| Sep 14, 26Sep 14, 2026 | WILSON TROY EDWARD Direct | Sell | $45.5K$45,500.00 |
| Sep 14, 26Sep 14, 2026 | Cesano Alessandra Direct | Sell | $567K$566,994.45 |
| Jul 6, 26Jul 6, 2026 | AUERBACH ALAN H Direct | Sell | $364.1K$364,051.25 |
| Jul 6, 26Jul 6, 2026 | HUNT DOUGLAS M Direct | Sell | $69.9K$69,904.98 |
| Jul 6, 26Jul 6, 2026 | NOUGUES MAXIMO F Direct | Sell | $77.6K$77,556.52 |
| Jun 12, 26Jun 12, 2026 | MOYES JAY M Direct | Sell | $158.8K$158,796.00 |
| Jun 12, 26Jun 12, 2026 | WILSON TROY EDWARD Direct | Sell | $77.7K$77,748.12 |
| Jun 12, 26Jun 12, 2026 | Stuglik Brian M Direct | Sell | $58.3K$58,311.09 |
| Jun 12, 26Jun 12, 2026 | Senderowicz Adrian Direct | Sell | $194.3K$194,310.90 |
1–10 of 17
Summary
Insiders reported 0 buys worth $0.00 and 17 sells worth $2.14M over the last 12 months. That adds up to net selling of $2.14M. AUERBACH ALAN H was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +210.9% | N/A1 analysts |
| Revenue | N/A | N/A | +0.0% | +0.2% (5yr)1 analysts |
| Net Income | N/A | N/A | +2396.3% | N/A1 analysts |
| EBIT | N/A | N/A | +16.3% | -24.3% (5yr)1 analysts |
Analysis
Recent growth has been strongest in Net Income at +2396.3% over three years. Forward estimates point to Revenue at +0.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Puma Biotechnology, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PBYI's management, answered from reported figures.
Who manages PBYI?
Puma Biotechnology, Inc. (PBYI) lists 10 active executives. The top listed executive is Kenneth Wiehe, Senior Vice President of Supply Chain & Manufacturing.
Are PBYI insiders buying or selling?
Recent insider activity shows net buying of $12.24M.
Continue the stock analysis
Jump to another research area for this company.